PON2 immunohistochemical expression was also evaluated in several molecular subtypes of breast cancer: luminal A, luminal B, luminal B HER2+, HER2+, and triple-negative breast cancer (TNBC). Here, ERBB2 is linked to triple-negative breast carcinoma.